Accelerating COVID-19 Therapeutic Interventions and Vaccines

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a groundbreaking public-private partnership established to create a coordinated framework for prioritizing and accelerating the most promising COVID-19 treatments and vaccines. Launched in April 2020 by the National Institutes of Health and its partners, it aimed to streamline clinical trials, prevent redundant research, and rapidly identify effective countermeasures against the SARS-CoV-2 virus. The initiative brought together expertise from across government agencies, biopharmaceutical companies, and academic institutions to address the global health emergency.

Background and launch

The ACTIV partnership was launched in response to the escalating global crisis caused by the COVID-19 pandemic, which had spread rapidly from Wuhan, China, to countries worldwide. Spearheaded by Francis S. Collins, then director of the National Institutes of Health, and Anthony Fauci of the National Institute of Allergy and Infectious Diseases, the initiative was formally announced in April 2020. Its creation was a direct outcome of discussions within the White House Coronavirus Task Force and built upon lessons from previous rapid research initiatives like the INSIGHT network for HIV/AIDS and the Partnership for Research on Ebola Virus in Liberia. The urgent need for a coordinated, non-competitive strategy to evaluate the flood of proposed therapeutic candidates, such as the initially touted hydroxychloroquine, was a primary catalyst for its formation.

Structure and governance

ACTIV operates through a multi-stakeholder governance model chaired by representatives from the National Institutes of Health and the Foundation for the National Institutes of Health. Its structure is organized into several focused working groups, each tackling specific aspects of the development pipeline. These groups include experts from the U.S. Food and Drug Administration, the European Medicines Agency, numerous pharmaceutical companies like Johnson & Johnson and Pfizer, and leading academic centers such as Duke University and the Mayo Clinic. A steering committee oversees the entire partnership, ensuring alignment on trial design, data sharing standards, and regulatory pathways, while a separate data and safety monitoring board provides independent oversight for clinical trials.

Key therapeutic initiatives

A major focus of ACTIV was the rapid design and execution of master protocol trials to test multiple therapeutic agents simultaneously. The flagship ACTIV-1 trial evaluated immunomodulators for hospitalized patients, while ACTIV-2 and ACTIV-3 investigated outpatient treatments and monoclonal antibodies, respectively. These trials rigorously assessed drugs like the interleukin-6 inhibitor tocilizumab and the antiviral remdesivir, which received an Emergency Use Authorization from the U.S. Food and Drug Administration. The partnership also prioritized the repurposing of existing drugs, screening compounds from the National Center for Advancing Translational Sciences to identify candidates with potential activity against SARS-CoV-2.

Key vaccine initiatives

While not directly developing vaccines, ACTIV played a crucial coordinating role in harmonizing the vaccine development landscape. It established standardized laboratory protocols, such as neutralizing antibody assays, to allow comparison of data across different vaccine candidates from developers like Moderna, AstraZeneca, and Novavax. The partnership's working groups developed animal model standards and contributed to the design of the COVID-19 Prevention Network's large-scale efficacy trials. This foundational work helped de-risk and accelerate the pivotal Phase III trials that led to the authorization of vaccines from Pfizer–BioNTech and Johnson & Johnson.

Funding and partnerships

ACTIV was funded through a combination of federal appropriations, including those from the National Institutes of Health and the Biomedical Advanced Research and Development Authority, and contributions from industry partners. The Foundation for the National Institutes of Health managed significant funds from private organizations, including the Bill & Melinda Gates Foundation and Wellcome Trust. In-kind contributions from over twenty major pharmaceutical companies provided access to proprietary compounds, clinical trial capacity, and scientific expertise. Collaborative agreements with international bodies like the World Health Organization and the European Medicines Agency aimed to ensure global alignment of research efforts.

Outcomes and impact

The ACTIV partnership significantly accelerated the evaluation of COVID-19 countermeasures, leading to several authorized treatments and contributing to the unprecedented speed of vaccine development. Its master protocol trials generated robust data that informed treatment guidelines by the National Institutes of Health and the World Health Organization. The initiative demonstrated the power of pre-competitive collaboration in a crisis, establishing new models for data sharing and trial design. The lessons and frameworks developed by ACTIV are now being examined for application to future pandemic preparedness, potentially influencing the mission of agencies like the Advanced Research Projects Agency for Health. Category:COVID-19 pandemic Category:National Institutes of Health Category:Medical and health organizations based in the United States